^
    Apply
    G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer (NCT03455270)
    Phase 1
    G1 Therapeutics, Inc.
    Completed
    Last update posted :
    12/15/2022
    Initiation :
    05/09/2018
    Primary completion :
    09/29/2022
    Completion :
    09/29/2022
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    Ibrance (palbociclib) • rintodestrant (G1T48)